BridgeBio Oncology Therapeutics (BBOT) to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025

Audio By Carbonatix

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Dec 23, 2024--

TheRas, Inc. d/b/a BridgeBio Oncology Therapeutics (“BBOT” or the “Company”), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced that the company’s Chief Executive Officer, Eli Wallace, PhD, will provide a company overview at the 43 rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025, at 9:30 a.m. PT, and will host one-on-one investor meetings in San Francisco, CA.

About TheRas, Inc. d/b/a BridgeBio Oncology Therapeutics (BBOT)

BridgeBio Oncology Therapeutics (BBOT) is a clinical-stage biopharmaceutical company advancing a next generation pipeline of novel small molecule therapeutics targeting RAS and PI3K malignancies. Initially formed as a subsidiary of BridgeBio, BBOT completed a $200M private financing with external investors in 2024 with the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors. For more information visit bridgebiooncology.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20241223276556/en/

CONTACT: BridgeBio Oncology Therapeutics (BBOT) Contact:

Idan Elmelech

Senior Vice President, Strategy & Business Development

[email protected]

(650) 405-7021

KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: BIOTECHNOLOGY HEALTH PHARMACEUTICAL CLINICAL TRIALS ONCOLOGY

SOURCE: BridgeBio Oncology Therapeutics

Copyright Business Wire 2024.

PUB: 12/23/2024 08:00 AM/DISC: 12/23/2024 08:03 AM

http://www.businesswire.com/news/home/20241223276556/en